Newsletter · · Ashutosh Agarwal

Medicare's GLP-1 Bridge Goes Live While IRA Round 2 Stays Quiet - Drug Pricing & IRA Round 2 - Week of July 6, 2026

Drug Pricing and IRA Round 2 newsletter for the week ending July 6, 2026. Medicare's GLP-1 Bridge went live July 1 at a $50 copay on a $245 net price, the 340B enforcement war escalated with Lilly cutting discounts and roughly 80 manufacturer lawsuits in the courts, while IRA Round 2 negotiation mechanics stayed off the podcast tape.

Drug Pricing & IRA Round 2

Week of July 6, 2026: Medicare's GLP-1 Bridge Goes Live While IRA Round 2 Stays Quiet

The single biggest drug-pricing event of the week wasn't a negotiation, a court ruling, or a tariff. It was Medicare quietly opening its checkbook for weight-loss drugs. On July 1, the Medicare GLP-1 Bridge Program went live, and for a program CMS insists is "temporary," it moves an awful lot of numbers.

Meanwhile, the storyline our book actually cares about (IRA Round 2 negotiation mechanics, the 2028 Part B list, the small-molecule "pill penalty," the EPIC Act) was essentially absent from podcasts this trailing week. So let's be honest about where the signal was, and where it wasn't.

TL;DR

  • Medicare's GLP-1 Bridge launched July 1 at a $50 flat copay, with the government paying a $245 net monthly price and taxpayers eating the $195 balance, a structural demand tailwind for Zepbound (LLY) and Wegovy (NVO) that runs through December 2027.
  • The 340B enforcement war escalated: Eli Lilly is cutting discounts to non-compliant hospitals, roughly 80 manufacturer lawsuits are grinding through the courts, and Senator Cassidy dropped fresh reform legislation. This is a real, live gross-to-net battle, one manufacturers are, for once, on the front foot in.
  • IRA Round 2 was quiet. No podcast this week did franchise-level revenue-at-risk work on JNJ, PFE, MRK, or BMY. Treat this issue's policy sections as color, not a catalyst.

What's New

1. The Medicare GLP-1 Bridge is real, and the mechanics matter. Multiple health-policy and clinician podcasts confirmed the same architecture. On Secure Your Retirement ("GLP-1 Medications and Medicare," June 29), Medicare specialist Sean Southerd (operator) laid it out: "It's starting July 1st, 2026… get that medication for $50 flat every month," with the program "scheduled to run through December 31st of 2027." It covers three drugs, "Fondeo, Wagovi, and Zepbound… the quick pen version." Why it moves numbers: Medicare has historically excluded weight-loss-only coverage, so this is net-new demand.

2. Follow the money on the Bridge. The independent Weight and Healthcare newsletter/podcast (pundit, July 1) put hard figures on it: manufacturers get "a net price of $245 per month," beneficiaries pay "$50," and "the $195 per month per person balance will be paid by U.S." taxpayers. Crucially, "the GLP-1 Bridge will operate outside of Medicare Part D," and the $50 copay "won't count toward their true out-of-pocket." The processor is Humana, the same Humana that "coughed up $122 million" over alleged Medicare Part D prescription fraud. For scale, the host cited the 2024 CBO estimate that covering GLP-1s for weight loss would cost Medicare "$35 billion from 2026 to 2034" against savings of just "$3.4 billion."

3. The Bridge is a foot in the door for something bigger. On Off the Chart (June 29), the Obesity Action Coalition's Tracy Zvenyach, Ph.D. (operator) explained that CMS wants to "transition it into the balance model in 2028," a state-Medicaid demonstration that "went live on May 1st of 2026" and could run through "December 2031" if Part D and Medicare Advantage plans opt in. Both programs "offer access to the GLP-1 medications at the same negotiated price." Translation: the temporary Bridge is scaffolding for durable federal obesity coverage.

4. The 340B enforcement wave is the week's live gross-to-net story. On 340B Insight ("How Courts Are Shaping the Future of 340B," June 29), 340B Health's Amanda Nagrotsky (insider) said manufacturers "primarily AbbVie, AstraZeneca, Novartis, as well as Pharma, have collectively filed about 80 lawsuits challenging state contract pharmacy protection laws," plus a separate AbbVie suit against HRSA arguing for a patient definition "significantly narrower than HRSA's" 1996 guidelines. She flagged two overhangs: HRSA's rebate-model pilot is "under review at the White House," and CMS is "expected to propose cuts to Part B drug reimbursement for 340B hospitals."

5. Lilly is unilaterally squeezing 340B, and getting away with it. On HFMA's Voices in Healthcare Finance (June 29), an American Hospital Association representative (operator) said Lilly "has unilaterally cut off that discount for a handful of hospitals" that didn't submit 340B claims data for both contract and in-house pharmacy drugs, with the policy set "February 1st" and enforcement biting "as of early June." The AHA's fear: "this just opened up the floodgates," with "half a dozen" other manufacturers, including Novo Nordisk, watching Lilly "get away with this." On Telltales (July 1), an analyst noted "16% of all drug sales in the U.S. are going through the 340B program," and that Bill Cassidy "put forward some legislation this week that revises the 340B program."

The Debate

"Manageable, modeled headwind." The bull framing: 340B is finally swinging toward manufacturers. Lilly is dictating terms, courts have handed pharma some patient-definition optionality, and Cassidy's bill could standardize data demands that shrink an inflated program, and NEBGH Voices (June 29) cited an IQVIA estimate that 340B pushes "roughly $6 billion in higher prices" onto commercial payers, so there's bipartisan appetite to rein it in. On GLP-1s, the Bridge is incremental volume Medicare never paid for before, a gift, at a $245 net price the manufacturers apparently accepted.

"Structural US margin compression." The bear framing: every one of these threads is the government methodically resetting US net prices lower. Dr. Oz, in his CMS Administrator capacity on the Hoover Institution's Capitalism and Freedom podcast (July 3), bragged the administration "will save about $600 billion for America over the next 10 years" via most-favored-nation deals and trumprx.gov. Citeline's Scrip ("Five Must-Know Things," June 29) confirmed "17 big pharma companies" have agreed MFN pricing that ties US Medicaid prices "in line with pricing in developed countries." Bridge, 340B rebates, MFN, and Round 2 negotiation all point the same direction: the US premium that funds global R&D is being negotiated away one program at a time. That's the version that eventually forces a small-molecule R&D pullback, the very "pill penalty" fear the podcasts didn't discuss this week but that lurks under all of it.

The swing factor: whether the Bridge's $245 net price becomes the reference point for future obesity pricing across Medicaid and MA. If it does, the "manageable" case gets a lot harder to argue.

Stocks in Play

LLY: Bull: Zepbound is one of three Bridge drugs, and Scrip cited Evaluate's forecast that tirzepatide (Mounjaro/Zepbound) hits "over 70 billion dollars by 2032, making it the biggest drug ever," with Lilly selling "over 137 billion dollars worth of drugs annually" by then. Bear: Lilly is the tip of the spear on 340B enforcement and a named MFN signatory, it's picking fights on price everywhere. Watch: whether other manufacturers follow Lilly's 340B data mandate, and Bridge uptake data.

NVO: Bull: Wegovy is a Bridge drug; Cagrisema approval is expected this year. Bear: Scrip flagged that Novo's semaglutide is "set to slip outside the 2032 top 10 bestsellers" on weaker weight loss versus tirzepatide, a share-loss story independent of policy. Watch: Cagrisema approval timing and any decision to match Lilly's 340B stance.

ABBV: Bull: it's the plaintiff driving the narrower 340B patient definition, and Skyrizi is projected the "second biggest selling drug in 2032, at over 33 billion dollars." Bear: litigation is a slow, binary grind, the Mississippi court already dismissed one AbbVie challenge "in its entirety." Watch: the HRSA patient-definition suit and Fourth Circuit contract-pharmacy rehearings.

AZN: Named among the ~80 340B litigants; no franchise-level podcast coverage this week. Watch: contract-pharmacy merits rulings.

JNJ, PFE, MRK, BMY: Quiet. No podcast this week analyzed their IRA franchise exposure (Stelara, Eliquis, Januvia, Pomalyst). Nothing new to trade off the tape.

Read-Throughs

  • Managed care / PBMs (HUM, CVS, CI, UNH): Humana is the Bridge's central processor, a modest new fee stream, and a curious pick given its Part D fraud history. The broader 340B rebate-model shift (possibly live "January 1st, 2027," per HFMA) reshapes gross-to-net for every PBM.
  • Biosimilars/generics (incl. TEVA): no direct coverage this week; the 340B and MFN fights are branded-manufacturer stories for now.
  • Small-mol vs biologic R&D mix: the pill-penalty debate stayed off-mic, but the MFN/340B/Bridge stack is the slow-burn setup for it.
  • Ex-US pricing: MFN explicitly imports developed-market prices into US Medicaid, the ex-US "reference basket" is now a US pricing input, not just a launch-strategy footnote.

What Changed vs Last Week

This is the first edition of this newsletter, no prior issue to compare against. On the specific franchise, IRA Round 2, and pill-penalty angles this book tracks: quiet week, no material updates. The action was in GLP-1 coverage expansion and 340B enforcement, not in the negotiation program itself.